KYTX (Kyverna Therapeutics) Long-Term Debt : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Long-Term Debt?

Kyverna Therapeutics's Long-Term Debt for the quarter that ended in Sep. 2024 was $0.00 Mil.

Kyverna Therapeutics Long-Term Debt Historical Data

The historical data trend for Kyverna Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Long-Term Debt Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Long-Term Debt

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial					-	-	-	-	-

Kyverna Therapeutics (NAS:KYTX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Kyverna Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.